Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Radiation Injuries 3Medulloblastoma 3Choroid Plexus Neoplasms 3Central Nervous System Neoplasms 3Brain Neoplasms 3Astrocytoma 3Pinealoma 2Oligodendroglioma 2Neuroectodermal Tumors, Primitive 2Meningioma 2Gliosarcoma 2Glioma, Subependymal 2Glioma 2Glioblastoma 2Ependymoma 2Craniopharyngioma 2Spinal Cord Neoplasms 1Optic Nerve Glioma 1Neurotoxicity Syndromes 1Neoplasm Metastasis 1Fatigue 1Familial ependymoma 1Cognitive Dysfunction 1

Interventions

Patient Reported Outcome Measures 2Neuropsychological Tests 2lithium sulfate 1XENP 1595 1Tablets 1Sodium Chloride 1Ramipril 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Quality of Life 1Pioglitazone 1Metformin 1Mental Status and Dementia Tests 1Memantine 1Lithium 1G(M1) Ganglioside 1Donepezil 1Climate Anxiety 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cognitive Dysfunction × Donepezil × CNS × Clear all
NCT00594633 2016-01-14

Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
25 enrolled
CNS

Brain Neoplasms, Central Nervous System Neoplasms, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡